Announcements Trials
Browse Landscape

Phase

Phase 2 11Phase 1 6Phase 1/2 2Phase EARLY_PHASE1 1

Status

Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Lymphoid 1

Conditions

Cytokine Release Syndrome 1Carcinoma, Non-Small-Cell Lung 1Burkitt Lymphoma 1

Interventions

Cyclophosphamide 250Radiotherapy 172pembrolizumab 154Carboplatin 146Gemcitabine 139Nivolumab 135Paclitaxel 129Dexamethasone 118Cisplatin 118fludarabine 115Rituximab 104Lenalidomide 103Bevacizumab 99Docetaxel 97Capecitabine 97fludarabine phosphate 92Temozolomide 89Cytarabine 89Oxaliplatin 87Etoposide 82Filgrastim 77Irinotecan 73Doxorubicin 73venetoclax 70Peripheral Blood Stem Cell Transplantation 68Fluorouracil 68Radiosurgery 66Melphalan 66Everolimus 66Bortezomib 66

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × OTHER × Interleukin 1 Receptor Antagonist Protein × Clear all
NCT05013450 2025-12-17

Dupilumab_Metastatic NSCLC

Icahn School of Medicine at Mount Sinai

Phase 1/2 Active not recruiting
33 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06703216 2025-06-15

PACER

Ann & Robert H Lurie Children's Hospital of Chicago

Phase 1/2 Not yet recruiting
24 enrolled
Lymphoid

Cytokine Release Syndrome, Burkitt Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡